JF
KNTE

Jump Financial’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Jump Financial’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-46,433
Closed -$141K – 2355
2023
Q2 		$141K Buy
+46,433
New +$179K 0.01% 1592
2023
Q1 		– Sell
-15,100
Closed -$92.1K – 2153
2022
Q4 		$92.1K Buy
+15,100
New +$123K ﹤0.01% 1436

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Jump Financial's KNTE Position: Q3 2023 in Review

Jump Financial sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q3 2023, closing a stake of 46,433 shares — an estimated $141K sold.

Jump Financial first reported a position in KNTE in Q4 2022 and held it in 2 quarters. The position peaked at $141K in Q2 2023. 58 funds tracked by Wall St. Rank hold KNTE as of Q3 2023.

  • Jump Financial reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Jump Financial sold 46,433 Kinnate Biopharma Inc. Common Stock shares in Q3 2023, an estimated $141K.
  • Jump Financial first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • Jump Financial's Kinnate Biopharma Inc. Common Stock position peaked at $141K in Q2 2023.
  • 58 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q3 2023.

Based on Jump Financial's 13F filing for Q3 2023, filed 7 Nov 2023.